Relevance of CAR genetic polymorphism and individual therapy

Abstract

Abstract:

Regulating phase I and II enzyme, drug transporters and constitutive androstane receptor (CAR) play an important role in dug metabolism and keeping balance on the levels of glucose, lipids and hormone in serum. As a hub of material metabolism within body, CAR can affect the efficacy of various drugs and be involved in many common metabolic diseases. Studying its polymorphism is referential for explaining the individual difference genetically and predicting the occurrence and development of diseases. This review focuses on the correlation between the CAR polymorphism and metabolic, which provides evidence for predicting the development of disease and choosing clinical drug dosage.

Key words: constitutive androstane receptor (CAR), polymorphism, material metabolism

CLC Number:

R968

WEI Wanhui, LI Ling, HE Mingyang, ZHAO Huijia, XU Qian, SHI Yuying, YUE Jiang, WANG Yanfeng, YE Qifa. Relevance of CAR genetic polymorphism and individual therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1432-1440.

References

［1］Baes M, Gulick T, Choi HS, et al. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements［J］. Mol Cell Biol, 1994, 14(3): 1544-1552.
［2］Choi HS, Chung M, Tzameli I, et al. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR［J］. J Biol Chem, 1997, 272(38): 23565-23571.
［3］Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta［J］. Nature, 1998, 395(6702): 612-615.
［4］Mackowiak B, Wang H. Mechanisms of xenobiotic receptor activation: Direct vs indirect ［J］. Biochim Biophys Acta, 2016, 1859(9): 1130-1140.
［5］Swart M, Whitehorn H, Ren Y, et al. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients ［J］. BMC Med Genet, 2012, 13: 112.
［6］Kobayashi K, Hashimoto M, Honkakoski P, et al. Regulation of gene expression by CAR: an update［J］. Arch Toxicol, 2015, 89(7): 1045-1055.
［7］Chai SC, Cherian MT, Wang YM, et al. Small-molecule modulators of PXR and CAR［J］. Biochim Biophys Acta, 2016, 1859(9): 1141-1154.
［8］Aleksunes LM, Klaassen CD. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARalpha-, and Nrf2-null mice［J］. Drug Metab Dispos, 2012, 40(7): 1366-1379.
［9］van der Mark VA, Rudi DWD, Shevchenko V, et al. Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells［J］. Drug Metab Dispos, 2017, 45(1): 56-67.
［10］Hedrich WD, Xiao J, Heyward S, et al. Activation of the constitutive androstane receptor increases the therapeutic index of CHOP in lymphoma treatment ［J］. Mol Cancer Ther, 2016, 15(3): 392-401.
［11］Cheung TP, Van Rostenberghe H, Ismail R, et al. High resolution melting analysis of the NR1I3 genetic variants: Is there an association with neonatal hyperbilirubinemia? ［J］. Gene, 2015, 573(2): 198-204.
［12］Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions［J］. Acta Pharm Sin B, 2016, 6(5): 413-425.
［13］Hori T, Moore R, Negishi M. p38 MAP kinase links CAR activation and inactivation in the nucleus via phosphorylation at threonine 38［J］. Drug Metab Dispos, 2016, 44(6): 871-876.
［14］Yasujima T, Saito K, Moore R, et al. Phenobarbital and insulin reciprocate activation of the nuclear receptor constitutive androstane receptor through the insulin receptor［J］. J Pharmacol Exp Ther, 2016, 357(2): 367-374.
［15］Wang X, Zheng L, Wu J, et al. Constitutive androstane receptor activation promotes bilirubin clearance in a murine model of alcoholic liver disease［J］. Mol Med Rep, 2017, 15(6): 3459-3466.
［16］Matsui K, Maruo Y, Sato H, et al. Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome［J］. BMC Gastroenterol, 2010, 10: 57.
［17］Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease ［J］. Metabolism, 2016, 65(8): 1026-1037.
［18］Marmugi A, Lukowicz C, Lasserre F, et al. Activation of the constitutive androstane receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way［J］. Toxicol Appl Pharmacol, 2016, 303: 90-100.
［19］Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy ［J］. Pharmacol Rev, 2014, 66(4): 948-983.
［20］Cheng S, Zou M, Liu Q, et al. Activation of constitutive androstane receptor prevents cholesterol gallstone formation ［J］. Am J Pathol, 2017, 187(4): 808-818.
［21］Schraplau A, Schewe B, Neuschafer-Rube F, et al. Enhanced thyroid hormone breakdown in hepatocytes by mutual induction of the constitutive androstane receptor (CAR, NR1I3) and arylhydrocarbon receptor by benzo［a］pyrene and phenobarbital［J］. Toxicology, 2015, 328: 21-28.
［22］Bing Y, Zhu S, Jiang K, et al. Reduction of thyroid hormones triggers down-regulation of hepatic CYP2B through nuclear receptors CAR and TR in a rat model of acute stroke［J］. Biochem Pharmacol, 2014, 87(4): 636-649.
［23］Supek F. The code of silence: widespread associations between synonymous codon biases and gene function［J］. J Mol Evol, 2016, 82(1): 65-73.
［24］van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity［J］. J Clin Oncol, 2009, 27(26): 4406-4412.
［25］van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib［J］. Clin Cancer Res, 2011, 17(3): 620-629.
［26］Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients ［J］. Pharmacogenomics J, 2008, 8(2): 139-146.
［27］Chew SC, Lim J, Singh O, et al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients ［J］. Eur J Clin Pharmacol, 2014, 70(2): 155-166.
［28］Wyen C, Hendra H, Siccardi M, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens ［J］. J Antimicrob Chemother, 2011, 66(9): 2092-2098.
［29］Olagunju A, Siccardi M, Amara A, et al. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients［J］. Ther Drug Monit, 2014, 36(6): 734-738.
［30］Zang M, Zhao L, Zhu F, et al. Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects ［J］. Drug Metab Pharmacokinet, 2015, 30(1): 123-126.
［31］Narjoz C, Cessot A, Thomas-Schoemann A, et al. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients［J］. Invest New Drugs, 2015, 33(1): 257-268.
［32］Tham LS, Holford NH, Hor SY, et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics ［J］. Clin Cancer Res, 2007, 13(23): 7126-7132.
［33］Cusato J, Tomasello C, Simiele M, et al. Efavirenz pharmacogenetics in a cohort of Italian patients［J］. Int J Antimicrob Agents, 2016, 47(2): 117-123.
［34］Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication ［J］. Antivir Ther, 2008, 13(5): 675-685.
［35］Lima LO, Bruxel EM, Hutz MH, et al. Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy［J］. Arq Bras Endocrinol Metabol, 2013, 57(7): 513-519.
［36］Moon JY, Chang BC, Lee KE, et al. Effects of pregnane x receptor genetic polymorphisms on stable warfarin doses ［J］. J Cardiovasc Pharmacol Ther, 2015, 20(6): 532-538.
［37］Dickinson L, Amin J, Else L, et al. Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs 600 mg) in treatment-naive hiv-infected patients: results of the encore1 study ［J］. Clin Pharmacol Ther, 2015, 98(4): 406-416.
［38］Olagunju A, Bolaji O, Amara A, et al. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study ［J］. Clin Infect Dis, 2015, 61(3): 453-463.
［39］Chen D, Guo F, Shi J, et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients ［J］. Drug Metab Pharmacokinet, 2014, 29(3): 249-253.
［40］Kaupert LC, Lemos-Marini SH, De Mello MP, et al. The effect of fetal androgen metabolism-related gene variants on external genitalia virilization in congenital adrenal hyperplasia ［J］. Clin Genet, 2013, 84(5): 482-488.
［41］Lima LO, Almeida S, Hutz MH, et al. PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms and lipid and lipoprotein levels in a Southern Brazilian population ［J］. Mol Biol Rep, 2013, 40(2): 1241-1247.
［42］Urano T, Usui T, Shiraki M, et al. Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density ［J］. Geriatr Gerontol Int, 2009, 9(3): 235-241.
［43］许新，纪莉莎，芦琳琳，等. 药物性肝损伤发病机制的研究进展［J］. 临床肝胆病杂志, 2016, 32(2): 382-385.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHOU Jing, ZHOU Chen, LIAO Ke, QIU Ailin, DONG Weilei, GUO Zifen. Correlation between progesterone receptor G1978T polymorphism and endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 400-406.
[4]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[5]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[6]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[7]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[8]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[9]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[10]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.
[11]	ZHOU Minmin, YU Lu, HAN Chao, GU Damin, LEI Daoyun. Relationship between human cholesteryl ester transfer protein rs5882 gene polymorphism and postoperative cognitive dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 768-774.
[12]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[13]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[14]	YANG Chunyan, ZHANG Wen, WANG Peipei, PENG Jing, JIANG Jia, SONG Jing, LIU Jun, LI Yueran, YANG Kui, WANG Sheng, XU Zhenyu, LUAN Jiajie. Distribution of gene polymorphism in folate metabolism pathway and its effect on serumhomocysteine concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1259-1264.
[15]	TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan. Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.